Human Leukocyte Antigen (HLA) Testing Market Research Report and Outlook by 2028

The human leukocyte antigen (HLA) market is anticipated to grow significantly, reaching an estimated US$ 1,155.65 million by 2028, up from US$ 697.74 million in 2021. This growth represents a compound annual growth rate (CAGR) of 7.5% from 2022 to 2028.

Several factors are contributing to the expansion of this market, including the rising number of plasma donations and organ transplantation procedures, as well as the broadening applications of HLA testing. However, challenges such as inaccuracies in testing can hinder market progress.

Human leukocyte antigens (HLAs) are unique proteins found on the surfaces of nearly all human cells, with the exception of red blood cells. HLA testing plays a crucial role in organ transplantation, which is often necessary for treating conditions like kidney failure, chronic liver cirrhosis, and chronic heart disease, among others. The increasing incidence of chronic illnesses and organ failure has led to a heightened demand for organ transplants and HLA testing. Prior to transplantation, HLA testing is essential to assess tissue compatibility between donors and recipients, thereby minimizing the risk of graft rejection. In recent years, organ transplantation has seen considerable success globally. According to the Global Observatory on Donation and Transplantation (GODT), a total of 129,681 organ transplants were performed in 2020, with 31.7% being living kidney transplants and 20.4% living liver transplants.

Various governments are actively promoting awareness regarding the importance of organ donation and the advantages of organ transplantation for specific medical treatments. For example, the Organ Procurement and Transplantation Network (OPTN) in the United States has implemented several initiatives aimed at increasing the number of organ transplants. These initiatives focus on enhancing organ and tissue transplants for patients suffering from end-stage organ diseases, revising organ distribution methods, and adjusting the organ transplantation waitlist to optimize the existing organ supply. Additionally, the OPTN has adopted innovative strategies to boost organ transplantation rates, such as maximizing the use of organs from deceased donors (including those who have experienced cardiac death or are brain-dead), minimizing organ discards, encouraging living donations, and increasing the authorization rates for potential organ donations. Consequently, the rising demand for organ transplants necessitates a greater supply of HLA testing kits and consumables, thereby propelling the growth of the HLA testing market.

The HLA market is categorized based on products and services into three segments: reagents and consumables, instruments, and software and services. In 2021, the reagents and consumables segment dominated the market share and is projected to exhibit the fastest CAGR of 7.5% during the forecast period.

When examining the market by technology, it is divided into molecular assay technologies and non-molecular assay technologies. The molecular assay technologies segment held a larger market share in 2021 and is expected to achieve a higher CAGR of 7.7% from 2022 to 2028.

In terms of end users, the HLA market is segmented into independent reference laboratories, hospitals and transplant centers, and other entities. The independent reference laboratories segment was the largest market share holder in 2021, while the hospitals and transplant centers segment is projected to experience the highest CAGR of 7.9% during the period from 2022 to 2028.

Key secondary sources utilized in the analysis of the human leukocyte antigen (HLA) market include the Global Observatory on Donation and Transplantation (GODT), the American Red Cross, the US Human Resource and Service Administration (HRSA), the Canadian Institute for Health Information, the National Registry of Transplants, the German Society for Thoracic and Cardiovascular Surgery (GSTCVS), the UK Health Security Agency, the Spanish National Transplant Organisation (ONT), the Japan Organ Transplant Network (JOTN), the Saudi Center for Organ Transplantation (SCOT), Business Monitor International (BMI), the South African Bone Marrow Registry (SABMR), and the World Health Organization (WHO).